Aging is an accumulation of damage to macromolecules, cells, tissues and organs. If any of that damage can be repaired, it can be repaired through rejuvenation. Developments in the field of medicine are advancing at an accelerated speed, ushering in the emergence of rejuvenation biotechnology.
Dr. Aubrey D.N.J. de Grey, a charismatic leader of a rising Rejuvenation Industry, is a British biogerontologist leading a global effort to end aging. The center of Dr. de Grey’s rejuvenation program is Strategies for Engineered Negligible Senescence (SENS) and creating the SENS Research Foundation.
SENS Research Foundation is a public charity that transforms the way the world researches and treats age-related diseases. The foundation is said to exist for a reason: to end aging. Since 2009, SENS Research Foundation has worked to turn into reality the concept of rejuvenation biotechnology which they defined as the repairing of the damage occurring to our bodies as we age. Their research and education programs, as well as awareness programs, have created the foundations of the Rejuvenation Biotechnology Industry. This industry is said to be capable of targeting age-related diseases with affordable, effective, and genuine cures.
There is no doubt that rejuvenation therapies through these kinds of technologies will become a reality at some point in the future. However, there is an underlying question of how accessible rejuvenation therapies will be. With technology that can extend life span and reduce the effects of aging, there is definitely a preconceived notion that it would only be for those rich enough to afford it.
But then, people also need to remember that new technologies generally start off as very costly and eventually, they become affordable. What’s relatively expensive now will cost much less in years, or even months from now.
A perfect example is the field of genomics. As LEAF points out, in 2001, sequencing just one person’s genome cost $100 million, it’s not a typo, that’s one hundred million bucks. It took only 15 years for full genome sequencing cost to drop to only $300, making personalised medicine reality globally. Another example are computers. During their earlier years, computers were huge machines with very limited capabilities. And only a handful of institutions, organizations, and companies could afford to buy them. However, as technology improved, the manufacturing process improved too. Consequently, computer production became easier and cheaper, resulting in what we are experiencing today – having a computer is no longer a luxury but a necessity. And almost everyone can afford to have one, even if it happens to be the cheapest model available in the market. The same thing happened with cars. In the beginning, only the rich could afford them. But as time went by, almost everyone had the capacity to buy one.
Looking back at history, there is no reason to believe the drop in cost would not be true of rejuvenation technologies too; especially when one takes into account an extremely strong economic motivator — the market for rejuvenation biotechnologies would be the largest in history. Every individual in the world would experience aging. Which means every person in the world will be a potential customer.